Literature DB >> 1185337

Hyperdibasicaminoaciduria, hyperammonemia, and growth retardation: Treatment with arginine, lysine, and citrulline.

A E Awrich, W J Stackhouse, J E Cantrell, J H Patterson, D Rudman.   

Abstract

A 9-year-old girl with hereditary dibasicaminoaciduria has been studied for three years. Initially, clinical features were: growth failure; anorexia and aversion to protein, spontaneous daily protein intake averaging only 10 gm; fasting and postprandial venous hyperammonemia; subnormal plasma concentrations of lysine, arginine, ornithine, and citrulline, with generalized hypermonobasicaminoacidemia; abnormally high renal clearances of lysine, arginine, and ornithine; and intestinal malabsorption of lysine and arginine. Intestinal absorption of citrulline, a precursor of arginine and ornithine, was normal. The patient was observed during four sequential 6-month periods as follows: no treatment (Period I); dietary supplement of arginine and lysine (Period II); dietary supplement of citrulline and lysine (Period III); no treatment (Period IV). During Periods II and III growth rate increased 3- to 4-fold, spontaneous protein intake increased 2- to 3-fold, and abnormalities in blood NH3 and the plasma aminogram were partially corrected. In most respects the citrulline plus lysine supplement was more beneficial than that of arginine plus lysine.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185337     DOI: 10.1016/s0022-3476(75)80296-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Authors:  Harri Niinikoski; Risto Lapatto; Matti Nuutinen; Laura Tanner; Olli Simell; Kirsti Näntö-Salonen
Journal:  JIMD Rep       Date:  2011-06-22

Review 2.  Food intolerance in humans.

Authors:  R H Herman; L Hagler
Journal:  West J Med       Date:  1979-02

3.  Growth hormone deficiency in a patient with lysinuric protein intolerance.

Authors:  Valentina Esposito; Teresa Lettiero; Simona Fecarotta; Gianfranco Sebastio; Giancarlo Parenti; Mariacarolina Salerno
Journal:  Eur J Pediatr       Date:  2006-06-15       Impact factor: 3.183

4.  A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance.

Authors:  Bridget M Stroup; Ronit Marom; Xiaohui Li; Chih-Wei Hsu; Cheng-Yen Chang; Luan D Truong; Brian Dawson; Ingo Grafe; Yuqing Chen; Ming-Ming Jiang; Denise Lanza; Jennie Rose Green; Qin Sun; J P Barrish; Safa Ani; Audrey E Christiansen; John R Seavitt; Mary E Dickinson; Farrah Kheradmand; Jason D Heaney; Brendan Lee; Lindsay C Burrage
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

5.  Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI.

Authors:  Mari Kärki; Kirsti Näntö-Salonen; Harri Niinikoski; Laura M Tanner
Journal:  JIMD Rep       Date:  2015-06-30

6.  Growth hormone studies in lysinuric protein intolerance.

Authors:  I Goto; T Yoshimura; Y Kuroiwa
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

7.  Treatment of a citrin-deficient patient at the early stage of adult-onset type II citrullinaemia with arginine and sodium pyruvate.

Authors:  K Mutoh; K Kurokawa; K Kobayashi; T Saheki
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

8.  Chiral recognition of amino acids by use of a fluorescent resorcinarene.

Authors:  Gerald I Richard; Hadi M Marwani; Shan Jiang; Sayo O Fakayode; Mark Lowry; Robert M Strongin; Isiah M Warner
Journal:  Appl Spectrosc       Date:  2008-05       Impact factor: 2.388

9.  Hyperdibasicaminoaciduria in a Turkish infant without evident protein intolerance.

Authors:  W Endres; G Zoulek; J Schaub
Journal:  Eur J Pediatr       Date:  1979-04-25       Impact factor: 3.183

10.  Lysinuric protein intolerance. Basolateral transport defect in renal tubuli.

Authors:  J Rajantie; O Simell; J Perheentupa
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.